Related Experiment Video
Updated: Jun 16, 2026
07:46
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
Microfluidic platforms for preclinical evaluation of immunotherapies
Angelo Massaro1, Charles W Blackledge1, Sarah E Shelton2
1Lampe Joint Department of Biomedical Engineering, North Carolina State University and University of North Carolina at Chapel Hill, Raleigh, North Carolina, USA.
Advanced Drug Delivery Reviews
|June 13, 2026
Summary
Microfluidic platforms offer precise control for preclinical immunotherapy testing, overcoming in vivo challenges. These advanced tools enhance the evaluation of immunomodulation, driving the development of novel immunotherapies.
Area of Science:
- Biomedical Engineering
- Immunology
- Drug Development
Background:
- Immunotherapy is a potent disease management strategy, but preclinical testing faces challenges due to complex in vivo factors.
- Understanding immune responses requires precise control over cellular, chemical, and physical environments, which is difficult to achieve in traditional models.
Purpose of the Study:
- To demonstrate the utility of microfluidic platforms for the preclinical evaluation of immunotherapies.
- To highlight existing and potential microfluidic tools for assessing immunomodulation therapies.
- To showcase how microfluidics can improve the efficiency of novel immunotherapy development.
Main Methods:
- Utilizing microfluidic platforms to create controlled environments for studying immune responses.
- Applying these platforms to evaluate pharmacokinetics and pharmacodynamics of immunotherapies.
- Reviewing existing literature on microfluidic applications in immunotherapy research.
Main Results:
- Microfluidic models enable precise control over experimental conditions, facilitating detailed analysis of immunotherapies.
- These platforms have already contributed to discoveries regarding immunotherapy delivery, efficacy, and safety.
- Demonstrated the potential for microfluidics to accelerate the generation of new immunotherapies.
Conclusions:
- Microfluidic platforms are valuable tools for overcoming preclinical immunotherapy testing challenges.
- These technologies offer enhanced control and insights for evaluating immunomodulation.
- Microfluidics can significantly drive the future development of effective immunotherapies.
